Gene patents: a crowded IP field

Since the end of the first era of genome sequencing with the conclusion of the human genome project, the challenge facing the life sciences industry has been to apply our understanding to practical applications.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Careers

Hogan Lovells makes senior public and administrative hire in Italy

18 February 2026 A lawyer with three decades of experience across energy, technology, life sciences, sports and media has joined the firm's Global Regulatory & IP practice in Milan.

Medtech

Danaher moves to acquire Masimo in $9.9bn deal

18 February 2026 The science and technology conglomerate’s big diagnostics bet comes with monitoring technology, an AI-powered product pipeline, and a litigation history that has kept Silicon Valley’s biggest player on the back foot.

Asia-Pacific

Generic rival blocked as AZ defends diabetes stronghold

17 February 2026 With a UK defeat still fresh, the Swedish-British drugmaker has secured breathing room in Australia—but a validity battle and key question of patent law looms at trial.

More features

Rooted in rights: Lessons from plant patent infringement and invalidity cases

How AI will be shaped by legal and regulatory developments in 2026

Key EU and UK regulatory changes to watch for in 2026

Regeneron v Alvotech: The big impact

Beyond traditional IP: A comprehensive AI strategy for life sciences

Prosecuting bispecific antibody patents: A cookbook for patent chefs

EU Pharma Package hits the final stretch—but can negotiators agree?

The clinical trial dilemma: Navigating European practice

Gene patents: a crowded IP field

More on this story

Editor's picks

Editor's picks

More features